← Back
Data updated: Mar 10, 2026
CEDIPROF INC
OncologyMetabolic
CEDIPROF INC is a specialty pharmaceutical company focused on Oncology, Metabolic.
2002
Since
5
Drugs
-
Trials
119
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
OSELTAMIVIR PHOSPHATE 2026-01-22
OSELTAMIVIR PHOSPHATE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 50%
1 drugs
Metabolic 50%
1 drugs
Pipeline Strength Pro
Loading...
Discontinued (2)
Company Info
- First Approval
- 2002-03-01
- Latest
- 2024-12-03
- Applications
- 5